Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.
Related Posts
Perplexity AI seeks valuation of about $9 billion in new funding round
Perplexity started the year with a roughly $500 million valuation and has continued attracting significant investor interest alongside the generative AI boom.
Raymond James upgrades these two telecom stocks as Trump election signals lower regulatory risk
Shares of U.S. Cellular and Telephone and Data Systems may be due for more gains following President-elect Donald Trump’s victory, according to Raymond James.
‘Oh, sh—’: RH CEO reacts live to stock tanking on tariffs, poor earnings
The executive also pointed out that the home furnisher has been contending with the “worst housing market in almost 50 years.”